Nevertheless, any CML patient that does have a BCR-ABL over 10% after 3 months of TKI presents a strong warning, requiring more careful and more frequent monitoring based on the clear RCT data. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.